Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 138 results for sclerosis

  1. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    dysfunction, as well as those with spinal cord injury, spina bifida and multiple sclerosis. Reports of its use in other conditions are...

    Research recommendation
    Published
    9 June 2015

  2. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)

    Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.

    Interventional procedures guidance
    Published
    23 August 2006
    View recommendations

    Sections for IPG188

  3. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    function. In the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in...

    Research recommendation
    Published
    9 June 2015

  4. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  5. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  6. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (IPG685)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

    Interventional procedures guidance
    Published
    27 January 2021
    View recommendations

    Sections for IPG685

  8. Transabdominal artificial bowel sphincter implantation for faecal incontinence (IPG276)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

    Interventional procedures guidance
    Published
    26 November 2008
    View recommendations

    Sections for IPG276

  9. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

    Interventional procedures guidance
    Published
    25 November 2015
    View recommendations

    Sections for IPG536

  10. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  11. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

    Technology appraisal guidance
    Published
    4 June 2025

    Sections for TA1069

  12. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (IPG299)

    Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.

    Interventional procedures guidance
    Published
    27 May 2009
    View recommendations

    Sections for IPG299

  14. Safety and efficacy of antimuscarinics:- What is the safety and efficacy of more recently developed antimuscarinics compared with (a) placebo/usual care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction?

    adults with impaired cognition (caused by cerebral involvement in multiple sclerosis or neurodegenerative diseases). Source guidance...

    Research recommendation
    Published
    9 June 2015

  15. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015